On March 6, 2024 Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), reported the upcoming presentation of two posters sharing new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting. The AACR (Free AACR Whitepaper) Annual Meeting will be held in San Diego from April 5-10 (Press release, Geneos Therapeutics, MAR 6, 2024, View Source [SID1234640883]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentations are as follows:

Title: Personalized neoantigen DNA vaccine GNOS-PV02 and pembrolizumab as second-line treatment for advanced hepatocellular carcinoma
Presenting Author: Mark Yarchoan, MD
Abstract Number: 1191
Poster Board Number: 25
Session Title: Tumor Immune Response 1
Session Date and Time: Sunday, Apr 7, 2024, 1:30 pm – 5:00 pm PT
Location: San Diego Convention Center, Poster Section 47

Title: Detection of circulating tumor DNA predicts survival in advanced HCC patients treated with personalized therapeutic DNA cancer vaccine in combination with immune checkpoint blockade
Presenting Author: Jian Yan, PhD
Abstract Number: 976
Poster Board Number: 17
Session Title: Circulating Nucleic Acids 1
Session Date and Time: Sunday, April 7, 2024, 1:30 pm – 5:00 pm PT
Location: San Diego Convention Center, Poster Section 40